Last reviewed · How we verify
PEG-interferon alfa-2b
PEG-interferon alfa-2b is a pegylated form of interferon alfa-2b that enhances and prolongs immune activation by binding to interferon-alpha receptors on immune cells.
PEG-interferon alfa-2b is a pegylated form of interferon alfa-2b that enhances and prolongs immune activation by binding to interferon-alpha receptors on immune cells. Used for Chronic hepatitis C, Chronic hepatitis B, Melanoma (adjuvant therapy).
At a glance
| Generic name | PEG-interferon alfa-2b |
|---|---|
| Also known as | PEG-IFN-alfa2b, PegIntron, SCH 54031, PEG-Intron, Pegasys |
| Sponsor | Barbara Ann Karmanos Cancer Institute |
| Drug class | Interferon alfa |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Biologic |
| Therapeutic area | Oncology, Immunology, Virology |
| Phase | FDA-approved |
Mechanism of action
Interferon alfa-2b is a cytokine that activates natural killer cells, macrophages, and T lymphocytes to enhance antiviral and antitumor immunity. The pegylation (attachment of polyethylene glycol) extends the drug's half-life and duration of action, allowing for less frequent dosing while maintaining therapeutic efficacy. This formulation is used primarily in chronic viral infections and certain malignancies.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
- Melanoma (adjuvant therapy)
- Follicular lymphoma
Common side effects
- Flu-like symptoms (fever, chills, fatigue)
- Headache
- Myalgia
- Depression
- Thrombocytopenia
- Neutropenia
- Anemia
- Injection site reactions
Key clinical trials
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia (PHASE2)
- Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (PHASE2)
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV (NA)
- Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors (NA)
- Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (PHASE1)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients (PHASE3)
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEG-interferon alfa-2b CI brief — competitive landscape report
- PEG-interferon alfa-2b updates RSS · CI watch RSS
- Barbara Ann Karmanos Cancer Institute portfolio CI